Cerebellar rTMS for the Treatment of Schizophrenic Patients
28 de abril de 2017 actualizado por: Alvaro Pascual-Leone, Beth Israel Deaconess Medical Center
Safety and Therapeutic Efficacy of Cerebellar Repetitive Transcranial Magnetic Stimulation in Patients With Schizophrenia
The primary aim of this protocol is to determine whether the use of repetitive transcranial magnetic stimulation (rTMS) over vermis of the cerebellum may be safe and therapeutically effective in patients with schizophrenia.
Because this is the first evaluation of this treatment in this population, the focus of this study is safety.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
8
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Beth Israel Deaconess Medical Center
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 65 años (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Age between 18-65 years
- Diagnosis of schizophrenia according to DSM-IV criteria(by a board-certified psychiatrist)
Exclusion Criteria:
- Prior neurosurgical procedures
- Any history of seizure
- Previous head injury
Contraindication to TMS:
- Implanted pacemaker
- Medication pump
- Vagal stimulator
- Deep brain stimulator
- Metallic hardware in the head or scalp: shrapnel, surgical clips, or fragments from welding
- Signs of increased intracranial pressure
- TENS unit and ventriculo-peritoneal shunt
- Pregnancy or lactating; note that a negative pregnancy test will be required if the patient is a female in reproductive years
- Advanced liver, kidney, cardiac, or pulmonary disease as defined clinically or a terminal medical diagnosis consistent with survival < 1 year
- A history of significant alcohol or drug abuse in the prior six months
- No focal cortical insult can be present, including tumor or vascular malformation
- Patients may not be actively enrolled in a separate intervention study
Patients unable to undergo a brain MR:
a. claustrophobia refractory to anxiolytics ferromagnetic metal in the body such as a prosthetic heart valve, a pacemaker, or a brain aneurysm clip).
- Change in antipsychotic medication during the last 4 weeks
- Any emergency psychiatry department visit during the last 4 weeks
- Been an inpatient in a psychiatry clinic within the last month
- Any other axis I diagnosis
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Safety of rTMS in schizophrenia patients
Participants will receive repetitive transcranial magnetic stimulation via MagPro x100 device to the vermis of cerebellum twice a day over 5 days
|
Participants will receive 10 repetitive transcranial magnetic stimulation sessions to the vermis of cerebellum using the MagPro x100 TMS device. These 10 rTMS sessions will be administered from Monday to Friday in five days, twice a day with a minimum of 4-hour gap between the sessions. Repetitive TMS will be applied with the intermittent theta burst pattern (iTBS). These parameters are known to cause excitation in brain activity. Anatomically precise localization of rTMS will be achieved using a frameless stereotactic system. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adverse Events
Periodo de tiempo: 3 weeks
|
Adverse event collection at baseline, daily for 5 days during treatment, every other day by phone until the final assessment at week 1 follow up visit.
|
3 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Positive and Negative Syndrome Scale (PANSS) - Positive Subscale
Periodo de tiempo: Baseline, 5 days (post-treatment), 1 week post treatment
|
Potential therapeutic efficacy was evaluated with the Positive and Negative Syndrome Scale (PANSS) Positive Subscale, a 7 item subscale measuring the presence/absence and severity of positive symptoms of schizophrenia.
The minimum score is 7 and the maximum score is 49, with higher values representing greater symptom severity.
Therapeutic efficacy was assessed at baseline, after 5 days of treatment, and 1 week post treatment.
The overall PANSS total score (minimum = 30, maximum = 210) is computed by summing the positive, negative, and general subscales; and higher values represent more severe schizophrenia psychopathology.
|
Baseline, 5 days (post-treatment), 1 week post treatment
|
|
Positive and Negative Syndrome Scale (PANSS) - Negative Subscale
Periodo de tiempo: Baseline, 5 days (post-treatment), 1 week post treatment
|
Potential therapeutic efficacy was evaluated with the Positive and Negative Syndrome Scale (PANSS) Negative Subscale, a 7 item subscale measuring the presence/absence and severity of negative symptoms of schizophrenia.
The minimum score is 7 and the maximum score is 49, with higher values representing greater symptom severity.
Therapeutic efficacy was assessed at baseline, after 5 days of treatment, and 1 week post treatment.
The overall PANSS total score (minimum = 30, maximum = 210) is computed by summing the positive, negative, and general subscales; and higher values represent more severe schizophrenia psychopathology.
|
Baseline, 5 days (post-treatment), 1 week post treatment
|
|
Positive and Negative Syndrome Scale (PANSS) - General Subscale
Periodo de tiempo: Baseline, 5 days (post-treatment), 1 week post treatment
|
Potential therapeutic efficacy was evaluated with the Positive and Negative Syndrome Scale (PANSS) General Subscale, a 16 item subscale measuring the presence/absence and severity of general psychopathology of schizophrenia.
The minimum score is 16 and the maximum score is 112, with higher values representing greater psychopathology severity.
Therapeutic efficacy was assessed at baseline, after 5 days of treatment, and 1 week post treatment.
The overall PANSS total score (minimum = 30, maximum = 210) is computed by summing the positive, negative, and general subscales; and higher values represent more severe schizophrenia psychopathology.
|
Baseline, 5 days (post-treatment), 1 week post treatment
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Alvaro Pascual-Leone, MD, PhD, Beth Israel Deaconess Medical Center
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de febrero de 2008
Finalización primaria (Actual)
1 de abril de 2009
Finalización del estudio (Actual)
1 de abril de 2009
Fechas de registro del estudio
Enviado por primera vez
19 de febrero de 2010
Primero enviado que cumplió con los criterios de control de calidad
19 de febrero de 2010
Publicado por primera vez (Estimar)
22 de febrero de 2010
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
5 de junio de 2017
Última actualización enviada que cumplió con los criterios de control de calidad
28 de abril de 2017
Última verificación
1 de abril de 2017
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2007P000395
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .